Addressing cardiovascular disease risks in diabetes patients
Diabetes is associated with microvascular diseases, primarily affecting the coronary arteries and the peripheral arteries. However, current diabetes therapies do not reduce cardiovascular events. In this context, the ERC-funded RGD-Diabetes project will search for a solution. Specifically, the research will focus on a circulating protein, IGF binding protein-1, which possesses several favourable characteristics (insulin sensitisation, amelioration of glucose intolerance, blood pressure lowering, reduced atherosclerosis and increased vascular repair). These effects are mediated by the interaction of the protein’s RGD-domain with cell-surface α5β1 integrin receptors, which increases insulin-stimulated glucose uptake in skeletal muscle cells and glucose-stimulated insulin secretion in pancreatic islets. The project will test whether RGD-integrin interaction could be exploited therapeutically in diabetes.
Fields of science
Funding SchemeERC-POC - Proof of Concept Grant
LS2 9JT Leeds
See on map